protopy
astellas pharma gmbh - takrolimuzas - dermatitas, atopinis - kiti dermatologiniai preparatai - suaugę pacientai, kurie nėra tinkamai reaguoja į įprastą terapiją arba netoleruoja, pvz., lokaliai vartojamų kortikosteroidų, gydymas vidutinio sunkumo ar sunkiu atopiniu dermatitu. vidutinio sunkumo ir sunkiu atopiniu dermatitu vaikams (2 metų ir vyresni), kurie nesugebėjo tinkamai reaguoti į vartojamais kortikosteroidais. palaikomasis gydymas nuo vidutinio iki sunkaus atopinio dermatito profilaktikos raketos ir pratęsti apšvietimo-nemokamai intervalais pacientams patirti aukšto dažnio ligos exacerbations (i. pasitaiko 4 ar daugiau kartų per metus), kuriems atlikta pirminiame atsakyme į ne daugiau kaip du kartus per parą takrolimuzo tepalu (pažeidimai pašalinami, beveik išnyko ar liko nežymus) 6 savaičių gydymo.
vaniqa
almirall, s.a. - eflornithine - hirsutizmas - kiti dermatologiniai preparatai - veido hirsutizmo gydymas moterims.
dupixent
sanofi winthrop industrie - dupilumabas - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatito veikėjai, išskyrus kortikosteroidus - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
arnikŲ tinktŪra valentis
valentis, uab - arnikų (arnica montana) žiedų tinktūra (1:10) - odos tirpalas - 1 ml/ml
kapsikam
grindeks as - dimetilsulfoksidas/kamparas, raceminis/terpentino eterinis aliejus/benzilnikotinatas/nonivamidas - tepalas - 50 mg/30 mg/30 mg/20 mg/2 mg/g - capsaicin and similar agents
hydrocortisone orifarm [hydrocortison takeda]
orifarm healthcare a/s - hidrokortizonas - gelis - 10 mg/g - hydrocortisone
laticort
pharmaswiss Česká republika s.r.o. - hidrokortizono butiratas - kremas - 1 mg/g - hydrocortisone butyrate
lorinden a
bausch health ireland limited - flumetazonas/salicilo rūgštis - tepalas - 0,2 mg/30 mg/g - flumetasone
lorinden c
pharmaswiss Česká republika s.r.o. - flumetazono pivalatas/kliokvinolis - tepalas - 0,2 mg/30 mg/g - flumetasone and antiseptics
minoxidil inteli
inteli generics nord, uab - minoksidilis - odos tirpalas - 50 mg/ml; 20 mg/ml - minoxidil